Form 4: Oric Pharmaceuticals Director Acquires 35,000 Stock Options

Lori Anne Kunkel, a director of Oric Pharmaceuticals, acquired 35,000 stock options on January 2, 2025, at an exercise price of $8.26.

Summary

• Lori Anne Kunkel, a director of Oric Pharmaceuticals, filed a Form 4 on January 6, 2025, reporting a transaction.
• On January 2, 2025, Kunkel acquired 35,000 stock options with an exercise price of $8.26.
• These options vest monthly over a 12-month period starting January 2, 2025, and expire on January 1, 2035.
• Following the transaction, Kunkel directly owns 35,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider confidence is generally positive, this is a routine filing.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This allows investors to monitor the actions of those with the most knowledge of the company's prospects.

Stakeholder Impact

• The acquisition of stock options by a director could positively influence shareholder sentiment.

Key Dates